Safety assessment of poloxamers 101, 105, 108, 122, 123, 124, 181, 182, 183, 184, 185, 188, 212, 215, 217, 231, 234, 235, 237, 238, 282, 284, 288, 331, 333, 334, 335, 338, 401, 402, 403, and 407, poloxamer 105 benzoate, and poloxamer 182 dibenzoate as used in cosmetics

International Journal of Toxicology

Volumn 27, Issue SUPPL. 2, 2008, Pages 93-128

  McLain, Valerie C ^a  

^a Cosmetic Ingredient Review ^*  (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ISPAGULA; NEOSPORIN; PIRACETAM; PLACEBO; POLAXAMER 101; POLAXAMER 108; POLAXAMER 184; POLAXAMER 407; POLOXAMER; POLOXAMER 105 BENZOATE; POLOXAMER 122; POLOXAMER 181; POLOXAMER 182; POLOXAMER 182 DIBENZOATE; POLOXAMER 183; POLOXAMER 184; POLOXAMER 185; POLOXAMER 215; POLOXAMER 217; POLOXAMER 231; POLOXAMER 234; POLOXAMER 235; POLOXAMER 237; POLOXAMER 238; POLOXAMER 282; POLOXAMER 288; POLOXAMER 333; POLOXAMER 334; POLOXAMER 335; POLOXAMER 402; UNCLASSIFIED DRUG; UNINDEXED DRUG;

ADVERSE OUTCOME; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ALKALINE PHOSPHATASE BLOOD LEVEL; AMES TEST; AMINOTRANSFERASE BLOOD LEVEL; ANGIOPLASTY; ANTIBACTERIAL ACTIVITY; ANTIMICROBIAL ACTIVITY; ANTINEOPLASTIC ACTIVITY; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; BACKACHE; BIOACCUMULATION; BLOOD CHEMISTRY; BODY WEIGHT; BRAIN; BRAIN BLOOD FLOW; BRAIN ISCHEMIA; BURN; CANCER CELL; CANCER RESISTANCE; CARCINOGENESIS; CARCINOGENIC ACTIVITY; CARDIOVASCULAR EFFECT; CELL VACUOLE; CHOLESTEROL BLOOD LEVEL; CLEARANCE; CLINICAL TRIAL; CONSTIPATION; CREATININE BLOOD LEVEL; CYTOTOXICITY; DIARRHEA; DOSE RESPONSE; DRUG ABSORPTION; DRUG BLOOD LEVEL; DRUG DELIVERY SYSTEM; DRUG DISTRIBUTION; DRUG EXCRETION; DRUG MEGADOSE; DRUG METABOLISM; DRUG SAFETY; DRUG SENSITIVITY; DRUG WITHDRAWAL; ENZYME ACTIVITY; EPITHELIUM CELL; ERYTHEMA; ESCHERICHIA COLI; EXPERIMENTAL DOG; EXPERIMENTAL RABBIT; EXPERIMENTAL RAT; EYE IRRITATION; FECES; GASTROINTESTINAL TRANSIT; GENE TRANSFER; GROWTH INHIBITION; HEADACHE; HEART INFARCTION; HEART MUSCLE NECROSIS; HEART REINFARCTION; HEMATOLOGY; HEMORRHAGIC SHOCK; HISTOCHEMISTRY; HOSPITALIZATION; HUMAN; HYDRATION; HYPERCHOLESTEROLEMIA; HYPERTRIGLYCERIDEMIA; IMMUNE FUNCTION TEST; INHALATION; INJECTION SITE PAIN; INJECTION SITE REACTION; INJECTION SITE SWELLING; KIDNEY PARENCHYMA; KIDNEY PROXIMAL TUBULE; KIDNEY TUBULE DISORDER; LD 50; LEG PAIN; LETHARGY; LISTERIA INNOCUA; LISTERIA MONOCYTOGENES; LIVER; LIVER CELL; LOADING DRUG DOSE; LOW DRUG DOSE; LUNG; LUNG ALVEOLITIS; MAXIMUM ALLOWABLE CONCENTRATION; METABOLIC ACTIVATION; MICROCOCCUS LUTEUS; MOLECULAR WEIGHT; MUTAGENICITY; MYCOBACTERIUM INTRACELLULARE AVIUM; NAUSEA; NEUROTOXICITY; NONHUMAN; ORGAN WEIGHT; PAIN; POLLAKISURIA; PSEUDOMONAS AERUGINOSA; PURIFICATION; REVIEW; RISK ASSESSMENT; SACCHAROMYCES CEREVISIAE; SALMONELLA TYPHIMURIUM; SERUM; SICKLE CELL ANEMIA; SIDE EFFECT; SKIN ABSORPTION; SKIN INFLAMMATION; SKIN IRRITATION; SKIN SENSITIZATION; SKIN TOXICITY; SOLUBILITY; SPARGING; STAPHYLOCOCCUS AUREUS; STAPHYLOCOCCUS EPIDERMIDIS; STAPHYLOCOCCUS INFECTION; STEADY STATE; STREPTOCOCCUS INFECTION; STREPTOCOCCUS PYOGENES; SURVIVAL; TISSUE ENGINEERING; TOXICITY TESTING; TRIACYLGLYCEROL BLOOD LEVEL; URINARY EXCRETION; WOUND HEALING; WOUND INFECTION; WOUND IRRIGATION;

ANIMALS; COSMETICS; DOSE-RESPONSE RELATIONSHIP, DRUG; HUMANS; LETHAL DOSE 50; MOLECULAR STRUCTURE; MUTAGENICITY TESTS; POLOXAMER; SKIN; TERATOGENS;

ANIMALIA; CANIS FAMILIARIS; ORYCTOLAGUS CUNICULUS; RATTUS;

EID: 53149118571     PISSN: 10915818     EISSN: 1092874X     Source Type: Journal    
DOI: 10.1080/10915810802244595     Document Type: Review

References (106)

1. Adams-Graves, P., A. Kedar, M. Koshy, et al. 1997. RheothRx (poloxamer 188) injection for the acute painful episode of sickle cell disease: A pilot study. Blood 90:2041-2046.
2. Alakhov, V., E. Klinski, S. Li, et al. 1999. Block copolymer-based formulation of doxorubicin. From cell screen to clinical trials. Colloids Surf. B Biointerfaces 16:113-134.
3. Anonymous. 1997. Featured excipient: Poloxamer. Int. J. Pharm. Compound 1:190-191.
4. Armstrong, J. K., H. J. Meiselman, and T. C. Fisher. 1995. Inhibition of red blood cell-induced platelet aggregation in whole blood by a nonionic surfactant, poloxamer 188 (RheothRx injection). Thromb. Res. 79:437-450.
5. Armstrong, J. K., H. J. Meiselman, R. B. Wenby, T. C. Fisher. 2001. Modulation of red blood cell aggregation and blood viscosity by the covalent attachment of pluronic copolymers. Biorheology 38:239-247.
6. 2
7. Batrakova, E. V., S. Lee, S. Li, A. Venne, V. Alakhov, and A. Kabanov. 1999. Fundamental relationships between the composition of pluronic block copolymers and their hypersensitization effect in MDR cancer cells. Pharm. Res. 16:1373-1379.
8. Batrakova, E. V., S. Li, V. Y. Alakhov, D. W. Miller, and A. V. Rabanov. 2003. Optimal structure requirements for pluronic block copolymers in modifying P-glycoprotein drug efflux transporter activity in bovine brain microvessel endothelial cells. J. Pharmacol. Exp. Ther. 304:845-854.
9. Batrakova, E. V., S. Li, S. V. Vinogradov, V. Y. Alakhov, D. W. Miller, and A. V. Rabanov. 2001a. Mechanism of pluronic effect on P-glycoprotein efflux system in blood-brain barrier: Contributions of energy depletion and membrane fluidization. J. Pharmacol. Exp. Ther. 299:483-493.
10. Batrakova, E. V., D. W. Miller, S. Li, V. Y. Alakhov, A. V. Rabanov, and W. F. Elmquist. 2001b. Pluronic P85 enhances the delivery of digoxin to the brain: In vitro and in vivo studies. J. Pharmacol. Exp. Ther. 296:551-557.
11. Batrakova, E. V., S. Li, W. F. Elmquist, D. W. Miller, V. Y. Alakhov, and A. V. Rabanov. 2001c. Mechanism of sensitization of MDR cancer cells by Pluronic block copolymers: Selective energy depletion. Br. J. Cancer 85:1987-1997.
12. Bentley, P. R., S. S. Davis, O. L. Johnson, R. C. Lowe, and C. Washington. 1989. Purification of pluronic F68 for perfluorochemical emulsfication. J. Pharm. Pharmacol. 41:661-663.
13. Blonder, J. M., L. Baird, J. C. Fulfs, and G. J. Rosenthal. 1999. Dose-dependent hyperlipidemia in rabbits following administration of Poloxamer 407 gel. Life Sci. 65:L261.
14. Cao, Y., X. Cai, L. Cui, Q. Shang, W. Liu, and W. Guan. 2002. Repair of porcine full-thickness skin defects with autologous tissue engineered skin. Zhonghua. Wai. Re. Za. Zhi. 40:24-26 [translated from Chinese].
15. Cao, Y., A. Rodriguez, M. Vacanti, C. Ibarra, C. Arevalo, and C. A. Vacanti. 1998. Comparative study of the use of poly(glycolic acid), calcium alginate and pluronics in the engineering of autologous porcine cartilage. J. Biomater. Sci. Polym. Ed. 9:475-487.
16. Carr, M. E., Jr., S. L. Carr, and A. A. High. 1996. Effects of poloxamer 407 on the assembly, structure and dissolution of fibrin clots. Blood Coagul. Fibronolysis. 7:109-113.
17. Carr, M. E., Jr., P. L. Powers, and M. R. Jones. 1991. Effects of poloxamer 188 on the assembly, structure and dissolution of fibrin clots. Thromb. Haemost. 66:565-568.
18. Chandler, D., M. R. Davey, K. C. Lowe, and B. J. Mulligan. 1987. Effects of emulsified perflurochemicals on growth and ultrastructure of microbial cells in culture. Biotechnol. Letts. 9:195-200.
19. Clarke, M. S., and P. L. McNeil. 1992. Syringe loading introduces macromolecules into living mammalian cell cytosol. J. Cell Sci. 102:533-541.
20. Clarke, M., M. Predergast, and A. Terry, Jr. 1999. Plasma membrane ordering agent pluronic F-68 reduces neurotransmitter uptake and release and produces learning and memory deficits in rats. Learning Memory 6:634-649.
21. Colbassani, H. J., D. L. Barrow, K. M. Sweeney, R. A. Bakay, I. J. Check, R. L. Hunter. 1989. Modification of acute focal ischemia in rabbits by poloxamer 188. Stroke 20:1241-1246.
22. Collaborative Organization for RheothRx Evaluation (CORE). 1997. Effects of RheothRx on mortality, morbidity, left ventricular function, and infarct size in patients with acute myocardial infarction. Collaborative Organization for RhethRx Evaluation (CORE). Circulation 96:192-201.
23. Comai, R., and A. C. Sullivan. 1980. Antiobesity activity of pluronic L-101. Int. J. Obesity 4:33-42.
24. Committee of Revision of the United States Pharmacopeial Convention. 1995. The United States Pharmacopeia, 18th ed., 2279-2281. Rockville, MD: United States Pharmacopeial Convention.
25. Connaughton, J., and C. F. McCarthy. 1982. Comparison of combination of ispaghula/poloxamer 188 and placebo on gastrointestinal transit time. Ir. Med. J. 75:93-94.
26. 2
27. 2
28. 2
29. 2
30. 2
31. 2
32. 2
33. 2
34. Davidorf, F. H., R. B. Chambers, O. W. Kwon, W. Doyle, P. Gresak, and F. Sylvan. 1990. Ocular toxicity of vitreal pluronic polyol F-127. Retina 10:297.
35. Dire, D. J., and A. P. Welsh. 1990. A comparison of wound irrigation solutions used in the emergency department. Ann. Emerg. Med. 19:704-708.
36. Edwards, C. M., G. P. Gambaretto, L. Conte, and K. C. Lowe. 1999. Evaluation of commercial and purified Pluronic F-68 in a human blood neutrophil bioassay. Artif. Cells Blood Substit. Immobil. Biotechnol. 27:171-177.
37. Edwards, C. M., J. A. May, S. Heptinstall, and K. C. Lowe. 1996. Effects of pluronic F-68 (poloxamer 188) on platelet aggregation in human whole blood. Thromb. Res. 81:511-512.
38. Edwards, C. M., S. Heptinstall, and K. C. Lowe. 1998. Pluronic F-68 inhibits agonist-induced platelet aggregation in human whole blood in vitro. Artif. Cells Blood Substit. Immobil. Biotechnol. 26:441-447.
39. Elibol, M., and F. Mavituna. Effect of perfluorodecalin as an oxygen carrier on actinorhodin production by Streptomyces coelicolor A3(2). Appl. Microbiol. Biotechnol. 43:206-210.
40. El-Kamel, A. H. 2002. In vitro and in vivo evaluation of Pluronic F127-based ocular delivery system for timolol maleate. J. Pharm. 241:47-55.
41. Follis, F., B. Jenson, K. Blisard, et al. 1996. Role of poloxamer 188 during recovery from ischemic spinal cord injury: A preliminary study. J. Invest. Surg. 9:149-156.
42. Food and Drug Administration (FDA). 2002. Frequency of use of cosmetic ingredients. FDA Database. Washington, DC: FDA.
43. Gosselin, A. M., and G. P. Biro. 1990. The cardiovascular effects of the surfactant pluronic F68 in anesthetized dogs. Adv. Exp. Med. Biol. 277:291-299.
44. Gottschalck, T. E., and G. N. McEwen, Jr. eds. 2004. International Cosmetic Ingredient Dictionary and Handbook, 10th ed. Washington, DC: CTFA.
45. Grindel, J. M., T. Jaworski, R. M. Emanuele, P. Culbreth. 2002. Pharmacokinetics of novel surface-active agent, purified poloxamer 188, in rat, rabbit, dog, and man. Biopharm. Drug. Dispos. 23:87-103.
46. Harkonene, P., S. Salo, T. Mattila-Sandholm, G. Wirtanen, D. G. Allison, and P. Gilbert. 1999. Development of a simple in vitro test system for the disinfection of bacterial biofilms. Water Sci. Technol. 39:219-225.
47. Howell, J. M., H. S. Dhindsa, T. O. Stair, and B. A. Edwards. 1993a. Effect of scrubbing and irrigation on staphylococcal and streptococcal counts in contaminated lacerations. Anitmicrob. Agents Chemother. 37:2754-2755.
48. Howell, J. M., T. O. Stair, A. W. Howell, D. J. Mudt, A. Falcone, S. R. Peters. 1993b. The effect of scrubbing and irrigation with normal saline, povidone iodine, and cefazolin on wound bacterial counts in a guinea pig model. Am. J. Emerg. Med. 11:134-138. Erratum in Am. J. Emerg. Med. 11:319.
49. Hunter, R. L., C. Ragannath, A. Tinkley, C. A. Behling, and F. Nolte. 1995. Enhancement of antibiotic susceptibility and suppression of Mycobacterium avium complex growth by poloxamer 331. Antimicrob. Agents. Chemother. 39:435-439.
50. 2
51. 2
52. Jewell, R. C., S. P. Khor, D. F. Kisor, K. A. LaCroix, and W. A. Wargin. 1997. Pharmacokinetics of RheothRx injection in healthy male volunteers. J. Pharm. Sci. 86:808-812.
53. Johnston, T. P., H. Beris, Z. G. Wout, and J. L. Kennedy. 1993. Effects on splenic, hepatic, hematological, and growth parameters following high-dose poloxamer 407 administration to rats. Int. J. Pharm. 100:279-284.
54. Johnston, T. P., and S. C. Miller. 1985. Toxicological evaluation of poloxamer vehicles for intramuscular use. J. Parenter. Sci. Technol. 39:83-89.
55. Johnston, T. P., and W. K. Palmer. 1993. Mechanism of poloxamer 407-induced hypertriglyceridemia in the rat. Biochem. Pharmacol. 46:1037-1042.
56. Johnston, T. P., and W. K. Palmer. 1997. Effect of poloxamer 407 on the activity of microsomal 3-hydroxy-3-methylglutaryl CoA reductase in rats. J. Cardiovasc. Pharmacol. 29:580-585.
57. Justicz, A. G., W. V. Farnsworth, M. S. Soberman, et al. 1991. Reduction of myocardial infarct size by poloxamer 188 and mannitol in a canine model. Am. Heart J. 122(3 Pt 1):671-680.
58. Kabanov, A. V., and V. Y. Alakhov. 2002. Pluronic block copolymers in drug delivery: From micellar nanocontainers to biological response modifiers. Crit. Rev. Ther. Drug Carrier Syst. 19:1-72.
59. Kier, L. D., L. M. Wagner, T. V. Wilson, et al. 1995. Cytotoxicity of ethylene oxide/propylene oxide copolymers in cultured mammalian cells. Drug. Chem. Toxicol. 18:29-41.
60. Kim, J. P., R. L. Peiffer, and R. E. Holman. 1988. Pluronic polyol: A potential alloplastic keratorefractive material. J. Cataract Refract. Surg. 14:312-316.
61. Kuo, J. H. 2003. Effect of pluronic-block copolymers on the reduction of serum-mediated inhibition of gene transfer of polyethyleneimine-DNA complexes. Biotechnol. Appl. Biochem. 37(Pt 3): 267-271.
62. Lane, T. A., and V. Krukonis. 1988. Reduction in the toxicity of a component of an artifical blood substitute by superficial fluid fractionation. Transfusion 28:375-378.
63. Leach, R. E., and R. L. Henry. 1990. Reduction of postoperative adhesions in the rat uterine horn model with poloxamer 407. Am. J. Obstet. Gynecol. 162:1317-1319.
64. Leaf, C. W. 1967. Toxicology of some non-ionic surfactants. Soap Chem. Spec. 43:48.
65. Lechmann, T., and W. H. Reinhart. 1998. The non-ionic surfactant Poloxamer 188 (RheothRx) increases plasma and whole blood viscosity. Clin. Hemorheol. Microcirc. 18:31-36.
66. Li, C., W. K. Palmer, and T. P. Johnston. 1996. Disposition of poloxamer 407 in rats following a single intraperitoneal injection assessed using a simplified colorimetric assay. J. Pharm. Biomed. Anal. 14:659-665.
67. Li, B., Y. J. Wang, C. Q. Ling, and W. J. Wang. 1998. Acute toxicity test of a new pharmaceutical adjuvant: Poloxamer 407. J. Chin. Pharm. 9:111-112 [translated from Chinese].
68. Liu, M. W., J. A. Hearn, J. F. Luo, P. G. Anderson, G. S. Roubin, S. Iyer, and L. Bilodou. 1996. Reduction of thrombus formation without inhibiting coagulation factors does not inhibit intimal hyperplasia after balloon injury in pig coronary arteries. Coron. Artery Dis. 7:667-670.
69. Lowe, K. C., B. A. Furmidge, and S. Thomas. 1995. Haemolytic properties of pluronic surfactants and effects of purification. Artif. Cells Blood Substit. Immobil. Biotechnol. 23:135-139.
70. Magnusson, G., O. Thomas, and J.-A. Nyberg. 1986. Toxicity of Pluronic F-68. Toxicol. Lett. 30:203-207.
71. Marino, D. J. 1987. Evaluation of Pluronic Polyol F127 as a vehicle for petroleum hydrocarbons in the salmonella/microsomal assay. Environ. Mutagen. 9:307-316.
72. Mayer, D. C., S. J. Strada, C. Hoff, R. L. Hunter, and M. Artman. 1994. Effects of poloxamer 188 in a rabbit model of hemorrhagic shock. Ann. Clin. Lab. Sci. 24:302-311.
73. Maynard, C., R. Swenson, and J. A. Paris. 1998. Randomized, controlled trial of RheothRx (poloxamer 188) in patients with suspected acute myocardial infarction. RheothRx in Myocardial Infarction Study Group. Am. Heart J. 135(5 Pt 1):797-804.
74. Mezrow, C. K., M. Mazzoni, D. Wolfe, H. H. Shiang, R. S. Litwak, and R. B. Griepp. 1992. Poloxamer 188 improves neurologic outcome after hypothermic circulatory arrest. J. Thorac. Cardiovasc. Surg. 103:1143-1146.
75. Miller, D. W., E. V. Batrakova, and A. V. Kabanov. 1999. Inhibition of multidrug resistance-associated protein (MRP) functional activity with pluronic block copolymers. Pharm. Res. 16:396-401.
76. Mizrahi, A. 1975. Pluronic polyols in human lymphocyte cell line cultures. J. Clin. Microbiol. 2:11-13.
77. Moghimi, S. M., and J. C. Murray. 1996. Poloxamer-188 revisited: A potentially valuable immune modulator. J. Natl. Cancer Inst. 88:766-768.
78. Moghimi, S. M., and A. C. Hunter. 2000. Poloxamers and poloxamines in nanoparticle engineering and experimental medicine. Trends Biotechnol. 184:412.
79. Murhammer, D. W., and C. F. Goochee. 1990. Sparged animal cell bioreactors: Mechanism of cell damage and Pluronic F68 protection. Biotechnol. Prog. 6:391-397.
80. Naim, J. O., D. Pulley, K. Scanlan, J. R. Hinshaw, and R. J. Lanzafame. 1993. Reduction of postoperative adhesions to Marlex mesh using experimental adhesion barriers in rats. J. Laparoendosc. Surg. 3:187-190.
81. Nalbandian, R. M., R. L. Henry, K. W. Balko, D. V. Adams, and N. R. Neuman. 1987. Pluronic F-127 gel preparation as an artificial skin in the treatment of third-degree burns in pigs. J. Biomed. Mater. Res. 21:1135-1148.
82. Nash, V. J, T. P. Johnston, and W. K. Palmer. 1996. Effects of nicotinic acid on poloxamer 407 induced hyperlipidemia. Pharmacotherapy 16:10-15.
83. O'Keefe, J. H., C. L. Grines, M. A. DeWood, et al. 1996. Poloxamer-188 as an adjunct to primary percutaneous transluminal coronary angioplasty for acute mycardial infarction. Am. J. Cardiol. 78:747-750.
84. Palmer, W. K., E. E. Emeson, and T. P. Johnston. 1998. Poloxamer 407-induced atherogenesis in the C57BL/6 mouse. Atherosclerosis 136:115-123.
85. Parnaud, G., S. Tache, G. Peiffer, and D. E. Corpet. 2001. Pluronic F68 block polymer, a very potent suppressor of carcinogenesis in the colon of rats and mice. Br. J. Cancer 84:90-93.
86. Port, D. C., P. J. Garvin, and C. E. Ganote. 1978. The effects of Pluronic F-38 (Polyoxamer 108) administered intravenously to rats. Toxicol. Appl. Pharmacol. 44:401-411.
87. Portoles, M., M. F. Refojo, and F. L. Leong. 1994. Poloxamer 407 as a bacterial adhesive for hydrogel contact lenses. J. Biomed. Mater. Res. 28:303-309.
88. Reigel, D. H., B. Bazmi, S. R. Shih, and M. D. Marquardt. 1993. A pilot investigation of poloxamer 407 for the prevention of leptomeningeal adhesions in the rabbit. Pediatr. Neurosurg. 19:250-255.
89. Rice, V. M., A. Shanti, K. S. Moghissi, and R. E. Leach. 1993. A comparative evalutation of Poloxamer 407 and oxidized regenerated cellulose (Interceed [TC7]) to reduce postoperative adhesion formation in the rat uterine horn model. Fertil. Steril. 59:901-906.
90. Rodeheaver, G. T., L. Kurtz, B. J. Kircher, and R. F. Edlich. 1976. Pluronic F68: A promising new skin wound cleanser. Am. J. Surg. 132:67.
91. Rodeheaver, G. T., L. Kurtz, B. J. Kircher, and R. F. Edlich. 1980. Pluronic F68: A promising new skin wound cleanser. Ann. Emerg. Med. 9:572-576.
92. Schaer, G. L., T. L. Hursey, S. L. Abrahams, et al. 1994. Reduction in reperfusion-induced myocardial necrosis in dogs by RheothRx injection (poloxamer 188 N. F.), a hemorheological agent that alters neutrophil function. Circulation 90:2964-2975.
93. Schaer, G. L., L. J. Spaccavento, K. F. Browne, et al. 1996. Beneficial effects of RheothRx injection in patients receiving thrombolytic therapy for acute myocardial infarction. Results of a randomized, double-blind placebo-controlled trial. Circulation 94:298-307.
94. Schmolka, I. R. 1994. Physical basis for poloxamer interactions. Ann. N Y Acad. Sci. 720:92-97.
95. Silk, M., and E. Sigman. 1972. Effect of pluronic F68 on the development of tumor metastasis. Cancer 29:171-172.
96. Steinleitner, A., H. Lamber, C. Kazensky, and B. Cantor. 1991. Poloxamer 407 as an intraperitoneal barrier material for the prevention of postsurgical adhesion formation and reformation in rodent models for reproductive surgery. Obstet. Gynecol. 77:48-52.
97. Toth, K., R. B. Wenby, H. J. Meiselman. 2000. Inhibition of polymer-induced red blood cell aggregation by poloxamer 188. Biorheology 37:301-312.
98. Ulrich, C. E., R. G. Geil, T. R. Tyler, G. L. Kennedy, and H. A. Birnbaum. 1992. Two-week aerosol inhalation study in rats of ethylene oxide/propylene oxide copolymers. Drug Chem. Toxicol. 15:269-270.
99. United States Pharmacopeia The National Formulary (USP National Formulary) 2004. Poloxamer entry. pp. 2908-2909. Rockville, MD: US Pharmacopeial Convention, Inc.
100. Van Belle, E., L. Maillard, A. Rivard, et al. 1998. Effects of poloxamer 407 on transfection time and percutaneous adenovirus-mediated gene transfer in native and stented vessels. Hum. Gene Ther. 9:1013-1024.
101. Wahl, R., and W. C. Butterfield. 1976. The prevention of ulcers in the pylorus-ligated rat by intravenous pluronic F68. J. Surg. Res. 20:45-47.
102. Wang, Z. Y., and I. J. Stern. 1975. Disposition in rats of a polyoxypropylene-polyoxyethylene copolymer used in plasma fractionation. Drug Metab. Dispos. 3:536-542.
103. West, J. L., and J. A. Hubbell. 1995. Comparison of covalently and physically cross-linked polyethylene glycol-based hydrogels for the prevention of postoperative adhesions in a rat model. Biomaterials 16:1153-1156.
104. Willcox, M. L., M. M. Newman, and B. C. Paton. 1978. A study of labeled pluronic F68 after intravenous injection into the dog. J. Surg. Res. 25:349-356.
105. Wout, Z. G., E. A. Pec, J. A. Maggiore, R. H. Williams, P. Palicharla, and T. P. Johnston. 1992. Poloxamer 407-mediated changes in plasma cholesterol and triglycerides following intraperitoneal injection to rats. J. Parenter. Sci. Technol. 46:192-200.
106. Xiao, N., X. C. Lu, H. S. Chen, Z. H. Yang, and K. L. Tian. 1989. Effect of fluorocarbon blood substitute on neutrophil phagocytic function. Zhongguo. Yao. Li. Xue. Bao. 10:537-539.